- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Changes to MEOS and Barriers to Entry
As terms for Monthly Enhanced Oncology Services (MEOS) payments are set to change under the EOM, panelists worry that the barriers to entry to value-based care will be too high for practices that did not participate in the OCM.
EP: 1.No Successor to OCM Would Disappoint
EP: 2.CMMI Open to Feedback, but EOM Out of the Blue
EP: 3.Some Practices That Did Not Do OCM Are Applying
EP: 4.Seven Tumor Types: Pros and Cons
EP: 5.A Model That Is Built to “Win”
EP: 6.Addressing Health Equity and Social Needs
EP: 7.Is Five Years Long Enough?
EP: 8.Changes to MEOS and Barriers to Entry
EP: 9.Small Practices and Dual Risk: Considerations and Approaches
EP: 10.Does Pooling Make Sense?
EP: 11.What Would You Change About the EOM?
Moderator Stuart Staggs, MSIE, senior director, strategic programs, The US Oncology Network, takes the discussion where everyone wants it to go: MEOS payments. What will lower payments—from $160 per patient per month to $70 for most patients, and $100 for those dually eligible for Medicare and Medicaid, mean for practices? Fred Divers, MD, chief medical officer, American Oncology Network and medical oncologist, Genesis Cancer and Blood Institute of Arkansas, highlights the lack of a copayment for patients as a plus of the EOM, and says it’s good there is extra revenue tied to caring for the Medicaid population. But Divers and Stephen Schleicher, MD, MBA, chief medical officer, Tennessee Oncology, both express concern about the barrier to entry issue for practices that most need to try value-based care. Kashyap Patel, MD, CEO, Carolina Blood and Cancer Care Associates and president, Community Oncology Alliance, says that CMMI would benefit from broader thinking about rewarding practices for attending to the global cost of care. Divers also notes the effect that inflation has had on practices, as the cost of supplies has increased.
AI's Role in Oncology: Supporting, Not Replacing, Health Care Providers
January 9th 2025In this second half of our interview with Vanderbilt University Medical Center’s Travis Osterman, DO, MS, FAMIA, FASCO, he discusses opportunities for advancing the smart use of artificial intelligence (AI) in cancer care.
Read More
Leveraging AI and Community Health Workers to Boost Trial Access
January 4th 2025In this second part of our interview with Kasey Bond, MPH, NYU Langone Health, we discuss the contributions of community health workers to increasing clinical trial access and how technology—artificial intelligence (AI), in particular—can help to facilitate the process.
Read More
